A Phase III, Randomized, Open-Label, Multi-Center, Global&#160;Study of Volrustomig (MEDI5752) as Sequential Therapy Versus&#160;Observation in Participants with Unresected Locally Advanced&#160;Head and Neck Squamous Cell Carcinoma, Who Have Not&#160;Progressed Following Definitive Concurrent Chemoradiotherapy&#160;(eVOLVE-HNSCC)<div><br /></div><div><b>D798EC00001</b><br /></div>

EVOLVE-HNSCC D798EC00001

Comprehensive Cancer Center Mainfranken

Kopf/Hals Tumoren

Kopf-Hals-Malignome

HPV16

PD-1 (Programmed cell death protein 1)

PD-L1

Phase III

Herr Prof. Dr. Dr. Urs Müller-Richter

Frau PD Dr. Barbara Deschler-Baier

Herr Dr. Horst-Dieter Hummel

Zentrum für Zahn-, Mund- und Kiefergesundheit

Universitätsklinikum Würzburg

Adjuvant

Therapeutisch